scholarly journals Deletion of interleukin-6 in mice with the dominant negative form of transforming growth factor β receptor II improves colitis but exacerbates autoimmune cholangitis

Hepatology ◽  
2010 ◽  
Vol 52 (1) ◽  
pp. 215-222 ◽  
Author(s):  
Weici Zhang ◽  
Masanobu Tsuda ◽  
Guo-Xiang Yang ◽  
Koichi Tsuneyama ◽  
Guanghua Rong ◽  
...  
Keyword(s):  
Growth Factor ◽  
Interleukin 6 ◽  
Transforming Growth Factor ◽  
Transforming Growth Factor Β ◽  
Dominant Negative ◽  
Autoimmune Cholangitis ◽  
Dominant Negative Form ◽  
Β Receptor ◽  
Negative Form

scholarly journals Deletion of interleukin-12p40 suppresses autoimmune cholangitis in dominant negative transforming growth factor β receptor type II mice

Hepatology ◽  
2009 ◽  
Vol 50 (5) ◽  
pp. 1494-1500 ◽  
Author(s):  
Katsunori Yoshida ◽  
Guo-Xiang Yang ◽  
Weici Zhang ◽  
Masanobu Tsuda ◽  
Koichi Tsuneyama ◽  
...  
Keyword(s):  
Growth Factor ◽  
Transforming Growth Factor ◽  
Transforming Growth Factor Β ◽  
Dominant Negative ◽  
Receptor Type ◽  
Type Ii ◽  
Autoimmune Cholangitis ◽  
Β Receptor

Adapting a transforming growth factor β–related tumor protection strategy to enhance antitumor immunity

Blood ◽  
2002 ◽  
Vol 99 (9) ◽  
pp. 3179-3187 ◽  
Author(s):  
Catherine M. Bollard ◽  
Claudia Rössig ◽  
M. Julia Calonge ◽  
M. Helen Huls ◽  
Hans-Joachim Wagner ◽  
...  
Keyword(s):  
Growth Factor ◽  
Transforming Growth Factor ◽  
Signal Transduction Pathway ◽  
Green Fluorescence Protein ◽  
Transforming Growth Factor Β ◽  
Dominant Negative ◽  
Barr Virus ◽  
Specific Ctls ◽  
Epstein Barr ◽  
Β Receptor

Abstract Transforming growth factor β (TGF-β), a pleiotropic cytokine that regulates cell growth and differentiation, is secreted by many human tumors and markedly inhibits tumor-specific cellular immunity. Tumors can avoid the differentiating and apoptotic effects of TGF-β by expressing a nonfunctional TGF-β receptor. We have determined whether this immune evasion strategy can be manipulated to shield tumor-specific cytotoxic T lymphocytes (CTLs) from the inhibitory effects of tumor-derived TGF-β. As our model we used Epstein-Barr virus (EBV)–specific CTLs that are infused as treatment for EBV-positive Hodgkin disease but that are vulnerable to the TGF-β produced by this tumor. CTLs were transduced with a retrovirus vector expressing the dominant-negative TGF-β type II receptor HATGF-βRII-Δcyt. HATGF-βRII-Δcyt– but not green fluorescence protein (eGFP)–transduced CTLs was resistant to the antiproliferative and anticytotoxic effects of exogenous TGF-β. Additionally, receptor-transduced cells continued to secrete cytokines in response to antigenic stimulation. TGF-β receptor ligation results in phosphorylation of Smad2, and this pathway was disrupted in HATGF-βRII-Δcyt–transduced CTLs, confirming blockade of the signal transduction pathway. Long-term expression of TGF-βRII-Δcyt did not affect CTL function, phenotype, or growth characteristics. Tumor-specific CTLs expressing HATGF-βRII-Δcyt should have a selective functional and survival advantage over unmodified CTLs in the presence of TGF-β–secreting tumors and may be of value in treatment of these diseases.

Sign in / Sign up

Export Citation Format

Share Document